January 27, 2014 / 12:20 PM / in 4 years

Pfizer says lung cancer drug fails two late-stage studies

Jan 27 (Reuters) - Pfizer Inc said its experimental lung cancer drug failed to meet its goals in two late-stage studies in patients with advanced non-small cell lung cancer.

The company said the drug, dacomitinib, did not show improved survival without the cancer worsening in patients when compared with another non-small cell lung cancer drug. The patients were previously treated with chemotherapy.

Pfizer said the drug did not prolong overall survival compared with a placebo in a second study.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below